methylphenidate has been researched along with Depression in 145 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD)." | 9.24 | The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder. ( Golubchik, P; Rapaport, M; Weizman, A, 2017) |
| " At study day 18, 85% of the methylphenidate and 60% of the placebo group were in depression remission (P = ." | 9.24 | Randomized, double-blind, placebo-controlled study of methylphenidate for the treatment of depression in SSRI-treated cancer patients receiving palliative care. ( Ganzini, L; Goy, E; Mongoue-Tchokote, S; Mori, M; Sullivan, DR, 2017) |
| "To evaluate the response of fatigue and depression in patients with advanced illness to titrated doses of methylphenidate (MP) as compared with placebo." | 9.16 | Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. ( Brazeau, DA; Brazeau, GA; Donnelly, JP; Drake, J; Kerr, CW; Milch, RA; Skretny, JA, 2012) |
| "Methylphenidate hydrochloride (Ritalin) has been used to treat both depression and apathy." | 9.05 | Methylphenidate in depression and states of apathy. ( Moore, DP, 1981) |
| "In the absence of definitive evidence of effectiveness, trials of low-dose methylphenidate in medically ill adults with depression, fatigue, or apathy, with monitoring for response and adverse effects, are appropriate." | 8.85 | Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. ( Hardy, SE, 2009) |
| "Methylphenidate dose was 5 mg every 2 hours as needed up to 20 mg per day." | 6.78 | Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. ( Allo, JA; Bruera, E; Cohen, MZ; Frisbee-Hume, S; Palmer, JL; Perez-Cruz, PE; Williams, JL; Yennurajalingam, S, 2013) |
| "Geriatric depression is common and is often associated with coexisting medical illnesses, cognitive dysfunction, or both." | 6.72 | Methylphenidate use in geriatric depression: A systematic review. ( Britt, RB; Brown, JN; Kahlon, CH; Smith, KR, 2021) |
| "Methylphenidate (MPH) is a stimulatory agent in brain with unknown long-term consequences." | 5.46 | Effects of acute doses of methylphenidate on inflammation and oxidative stress in isolated hippocampus and cerebral cortex of adult rats. ( Fatima, S; Motaghinejad, M; Motevalian, M; Shabab, B, 2017) |
| " At study day 18, 85% of the methylphenidate and 60% of the placebo group were in depression remission (P = ." | 5.24 | Randomized, double-blind, placebo-controlled study of methylphenidate for the treatment of depression in SSRI-treated cancer patients receiving palliative care. ( Ganzini, L; Goy, E; Mongoue-Tchokote, S; Mori, M; Sullivan, DR, 2017) |
| "The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD)." | 5.24 | The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder. ( Golubchik, P; Rapaport, M; Weizman, A, 2017) |
| " To determine (1) the serum baseline daily variations and nocturnal excretion of melatonin in ADHD subtypes and (2) the effect of chronic administration of methylphenidate, as well as the effects on symptomatology, 136 children with ADHD (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision: DSM-IV-TR criteria) were divided into subgroups using the "Children's Depression Inventory" (CDI)." | 5.19 | Methylphenidate ameliorates depressive comorbidity in ADHD children without any modification on differences in serum melatonin concentration between ADHD subtypes. ( Cubero-Millán, I; Fernández-López, L; Luna-del-Castillo, JD; Machado-Casas, I; Martínez-Serrano, S; Molina-Carballo, A; Muñoz-Hoyos, A; Ruiz-López, A; Tortosa-Pinto, P; Uberos, J, 2014) |
| "To evaluate the response of fatigue and depression in patients with advanced illness to titrated doses of methylphenidate (MP) as compared with placebo." | 5.16 | Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. ( Brazeau, DA; Brazeau, GA; Donnelly, JP; Drake, J; Kerr, CW; Milch, RA; Skretny, JA, 2012) |
| "While our review suggests that some psychostimulants-particularly methylphenidate-appear well-tolerated and demonstrate some efficacy for depression, as well as fatigue and sleepiness, the strength of evidence in our estimates was low to very low for most agents given the small sample sizes, few RCTs, and imprecision in most estimates." | 5.12 | Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis. ( Bahji, A; Mesbah-Oskui, L, 2021) |
| "Methylphenidate hydrochloride (Ritalin) has been used to treat both depression and apathy." | 5.05 | Methylphenidate in depression and states of apathy. ( Moore, DP, 1981) |
| "This review potentially supports the use of methylphenidate for opioid-induced sedation, cognitive decline and fatigue in cancer patients." | 4.98 | The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review. ( Andrew, BN; Guan, NC; Jaafar, NRN, 2018) |
| "The use of traditional psychostimulants (methylphenidate and dexamphetamine) and stimulant-like drugs (modafinil and armodafinil) for the treatment of depression is a growing concern given the lack of research evidence supporting their effectiveness." | 4.93 | Stimulants for depression: On the up and up? ( Bassett, D; Boyce, P; Byrow, Y; Hopwood, M; Lyndon, W; Malhi, GS; Mulder, R; Murray, G; Porter, R; Singh, A, 2016) |
| "Although most research to date has focused on the use of methylphenidate for the relief of symptoms such as asthenia and depression in cancer patients, there is growing interest in the use of modafinil, a psychostimulant with a structure and mechanism that differs from other drugs belonging to this group." | 4.87 | The use of psychostimulants in cancer patients. ( Centeno, C; Portela, MA; Rubiales, AS, 2011) |
| "In the absence of definitive evidence of effectiveness, trials of low-dose methylphenidate in medically ill adults with depression, fatigue, or apathy, with monitoring for response and adverse effects, are appropriate." | 4.85 | Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. ( Hardy, SE, 2009) |
| "On the basis of this review, we came to the conclusion that methylphenidate is used to ameliorate opioid-induced somnolence, to augment the analgesic effects of opioids, to treat depression, and to improve cognitive function in patients with cancer." | 4.81 | Palliative uses of methylphenidate in patients with cancer: a review. ( Dreisbach, A; Kahn, MJ; Lertora, JJ; Rozans, M, 2002) |
| "A total of 3354, 935 and 105 patients diagnosed with depression redeemed prescriptions for methylphenidate, modafinil or amphetamine/dexamphetamine/lisdexamphetamine, respectively." | 3.96 | The use of stimulants in depression: Results from a self-controlled register study. ( Brink, P; Nielsen, J; Rohde, C; Østergaard, SD, 2020) |
| "There has been increasing interest in the use of methylphenidate for cancer-related fatigue (CRF) in patients with advanced cancer." | 3.77 | Factors associated with response to methylphenidate in advanced cancer patients. ( Bruera, E; Chacko, R; Palmer, JL; Yennurajalingam, S, 2011) |
| "Hospital charts were reviewed for 66 medical and surgical patients who received dextroamphetamine or methylphenidate to treat a depressive disorder." | 3.67 | Psychostimulant treatment of depressive disorders secondary to medical illness. ( Cassem, NH; Murray, GB; Tesar, GE; Woods, SW, 1986) |
| "Although the FDA recommends imipramine hydrochloride (IMI) only for temporary relief of symptoms of enuresis nocturna (EN), the drug has been applied to a number of other pediatric situations, including the Hyperkinetic Syndrome (HS), childhood depression, somnambulism and pavor nocturnus, school phobia, petit mal epilepsy, allergies, autism, encorpresis and head-banging." | 3.65 | Imipramine and children: a review and some speculations about the mechanism of drug action. ( Gualtieri, CT, 1977) |
| "The outcome measurements included Mental Fatigue Scale, Choice Reaction Time, Compensatory Tracking Task, Mental Arithmetic Test, Digit Symbol Substitution Test, Mini-Mental State Examination (MMSE), Beck Depression Inventory (BDI), and Hamilton Rating Scale for Depression." | 2.84 | Efficacy of methylphenidate for the treatment of mental sequelae after traumatic brain injury. ( Wang, YF; Zhang, WT, 2017) |
| "Methylphenidate dose was 5 mg every 2 hours as needed up to 20 mg per day." | 2.78 | Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. ( Allo, JA; Bruera, E; Cohen, MZ; Frisbee-Hume, S; Palmer, JL; Perez-Cruz, PE; Williams, JL; Yennurajalingam, S, 2013) |
| "Methylphenidate is a psychostimulant that has been used to relieve depressive symptoms in advanced cancer patients." | 2.77 | Multicentre, double-blind, randomised placebo-controlled clinical trial on the efficacy of methylphenidate on depressive symptoms in advanced cancer patients. ( Almaraz, MJ; Centeno, C; Cuervo, MA; Gonzalez, J; Hernansanz, S; Lama, M; Nabal, M; Pascual, A; Ramos, D; Sanz, A; Vara, F, 2012) |
| "Methylphenidate was well tolerated in these patients with DAT." | 2.75 | Methylphenidate for apathy and functional status in dementia of the Alzheimer type. ( Bhatia, SC; Burke, WJ; Padala, PR; Petty, F; Potter, JF; Shostrom, VK; Wengel, SP, 2010) |
| "Depression is a common morbidity after traumatic brain injury." | 2.72 | Therapeutic benefits of pharmacologic and nonpharmacologic treatments for depressive symptoms after traumatic brain injury: a systematic review and network meta-analysis. ( Carvalho, AF; Chen, TY; Chen, YW; Cheng, YS; Chu, CS; Hsu, CW; Lei, WT; Li, DJ; Liang, CS; Lin, PY; Stubbs, B; Sun, CK; Tseng, PT; Tu, YK; Wu, CK; Wu, MK; Wu, YC; Yeh, TC, 2021) |
| "Geriatric depression is common and is often associated with coexisting medical illnesses, cognitive dysfunction, or both." | 2.72 | Methylphenidate use in geriatric depression: A systematic review. ( Britt, RB; Brown, JN; Kahlon, CH; Smith, KR, 2021) |
| "Some evidence indicates that bipolar depression may be more responsive to dopaminergic agents, suggesting that adjunctive stimulant medication may be an effective treatment for bipolar depression as well as for medication-induced sedation." | 2.71 | Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. ( Carlson, PJ; Merlock, MC; Suppes, T, 2004) |
| "Methylphenidate appears to be a safe and effective intervention in early poststroke rehabilitation that may expedite recovery." | 2.69 | Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. ( Blackwell, B; Chrostowski, J; Grade, C; Redford, B; Toussaint, L, 1998) |
| "Methylphenidate was intermediate in efficacy between d-amphetamine and l-amphetamine." | 2.64 | Comparative effects of d-amphetamine, l-amphetamine, and methylphenidate on mood in man. ( Davis, JM; Smith, RC, 1977) |
| "Methylphenidate is a psychostimulant originally used for the treatment of attention-deficit disorder." | 2.48 | Methylphenidate: established and expanding roles in symptom management. ( Prommer, E, 2012) |
| "Asperger syndrome is associated with various dysfunctional and problematic behaviors, in addition to the core features of communication and social skills dysfunction that define these conditions." | 2.44 | [Pharmacologic treatment of Asperger syndrome]. ( Yamada, S, 2007) |
| "Methylphenidate (Ritalin) is a commonly used central nervous stimulant." | 2.41 | Ritalin revisited: does it really help in neurological injury? ( Kajs-Wyllie, M, 2002) |
| "Treatment with methylphenidate has been advocated in patients with traumatic brain injury and stroke, cancer patients, and those with human immunodeficiency virus infection." | 2.41 | Methylphenidate: its pharmacology and uses. ( Challman, TD; Lipsky, JJ, 2000) |
| "Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1." | 2.41 | Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001) |
| "The concomitant use of MPHs and SSRIs showed generally safe profiles in adolescent ADHD patients with depression." | 1.91 | Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit/hyperactivity disorder with comorbid depression: ( Alhambra, DP; Kim, C; Kim, SJ; Lee, DY; Lee, J; Lee, S; Lee, YH; Park, J; Park, RW; Shin, Y; Tan, EH; Yang, SJ, 2023) |
| "Methylphenidate (MPH) is a common and effective treatment for attention deficit hyperactivity disorder (ADHD), but little is known about the relationship between early childhood intake of MPH and onset of antidepressant treatment during adolescence." | 1.51 | Childhood methylphenidate adherence as a predictor of antidepressants use during adolescence. ( Akriv, A; Ghilai, A; Hoshen, M; Krivoy, A; Leventer-Roberts, M; Madjar, N; Shlosberg, D; Shoval, G; Zalsman, G, 2019) |
| "Childhood narcolepsy is associated with various emotional, behavioural and cognitive dysfunctions as well as with psychiatric and neurodevelopmental disorders: anxiety, depression, attention deficit hyperactivity disorder and psychosis." | 1.48 | Childhood narcolepsy and autism spectrum disorders: four case reports. ( Dudova, I; Hrdlicka, M; Mohaplova, M; Nevsimalova, S; Prihodova, I, 2018) |
| "Methylphenidate (MPH) is a stimulatory agent in brain with unknown long-term consequences." | 1.46 | Effects of acute doses of methylphenidate on inflammation and oxidative stress in isolated hippocampus and cerebral cortex of adult rats. ( Fatima, S; Motaghinejad, M; Motevalian, M; Shabab, B, 2017) |
| "At baseline and at weeks 4 and 8, the parents evaluated their children, who were receiving treatment with osmotic-release oral system methylphenidate (mean dosage 36." | 1.40 | Parental quality of life and depressive mood following methylphenidate treatment of children with attention-deficit hyperactivity disorder. ( Chang, JS; Cho, SC; Hwang, JW; Kim, B; Kim, BN; Kim, Y, 2014) |
| " We have not found examples of ADHD in children who use increased dosage of sustained release of methylphenidate leading to depressive symptomatology." | 1.38 | Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder. ( Lakić, A, 2012) |
| "Methylphenidate (MPH) is a psychostimulant used in the treatment of attention-deficit/hyperactivity disorder in children and adults." | 1.38 | Chronic methylphenidate administration in mice produces depressive-like behaviors and altered responses to fluoxetine. ( Brookshire, BR; Jones, SR, 2012) |
| " Methylphenidate (MP) appears safe when used in the treatment of depression and fatigue in advanced cancer." | 1.36 | Methylphenidate side effects in advanced cancer: a retrospective analysis. ( Davis, MP; Khoshknabi, DS; Lasheen, W; Mahmoud, F; Rivera, N; Walsh, D, 2010) |
| "A patient with advanced pancreatic cancer is presented to demonstrate the clinical challenge of diagnosing depression in palliative care." | 1.31 | Depression with psychomotor retardation: diagnostic challenges and the use of psychostimulants. ( Bruera, E; Pereira, J, 2001) |
| "This article focuses on the treatment of depression with special reference to pharmacotherapy." | 1.26 | The pharmacologic treatment of depression. ( Denber, HC, 1979) |
| "Depression is an important cause of behavioral disturbances in children." | 1.26 | Childhood depression: an explanation of a behavior disorder of children. ( Brumback, RA; Weinberg, WA, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 67 (46.21) | 18.7374 |
| 1990's | 8 (5.52) | 18.2507 |
| 2000's | 26 (17.93) | 29.6817 |
| 2010's | 37 (25.52) | 24.3611 |
| 2020's | 7 (4.83) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, C | 1 |
| Lee, DY | 1 |
| Park, J | 1 |
| Yang, SJ | 2 |
| Tan, EH | 1 |
| Alhambra, DP | 1 |
| Lee, YH | 1 |
| Lee, S | 1 |
| Kim, SJ | 1 |
| Lee, J | 1 |
| Park, RW | 1 |
| Shin, Y | 1 |
| Martiny, K | 1 |
| Nielsen, NP | 1 |
| Wiig, EH | 1 |
| Rohde, C | 1 |
| Brink, P | 1 |
| Østergaard, SD | 1 |
| Nielsen, J | 1 |
| Cândido, RCF | 1 |
| Menezes de Padua, CA | 1 |
| Golder, S | 1 |
| Junqueira, DR | 1 |
| Cheng, YS | 1 |
| Tseng, PT | 1 |
| Wu, YC | 1 |
| Tu, YK | 1 |
| Wu, CK | 1 |
| Hsu, CW | 1 |
| Lei, WT | 1 |
| Li, DJ | 1 |
| Chen, TY | 1 |
| Stubbs, B | 1 |
| Carvalho, AF | 1 |
| Liang, CS | 1 |
| Yeh, TC | 1 |
| Chu, CS | 1 |
| Chen, YW | 1 |
| Lin, PY | 1 |
| Wu, MK | 1 |
| Sun, CK | 1 |
| Smith, KR | 1 |
| Kahlon, CH | 1 |
| Brown, JN | 1 |
| Britt, RB | 1 |
| Bahji, A | 1 |
| Mesbah-Oskui, L | 1 |
| Andrew, BN | 1 |
| Guan, NC | 1 |
| Jaafar, NRN | 1 |
| Golubchik, P | 1 |
| Rapaport, M | 1 |
| Weizman, A | 1 |
| Lazenka, MF | 1 |
| Freitas, KC | 1 |
| Henck, S | 1 |
| Negus, SS | 1 |
| Zhang, WT | 1 |
| Wang, YF | 1 |
| Ter Keurst, A | 1 |
| Tuerlings, JHAM | 1 |
| Bertholet, EA | 1 |
| Wijnen, HW | 1 |
| Padala, PR | 2 |
| Padala, KP | 1 |
| Lensing, SY | 1 |
| Ramirez, D | 1 |
| Monga, V | 1 |
| Bopp, MM | 1 |
| Roberson, PK | 1 |
| Dennis, RA | 1 |
| Petty, F | 2 |
| Sullivan, DH | 1 |
| Burke, WJ | 2 |
| Delsalle, P | 1 |
| Schuster, JP | 1 |
| von Gunten, A | 1 |
| Limosin, F | 1 |
| Ramon-Duaso, C | 1 |
| Gener, T | 1 |
| Consegal, M | 1 |
| Fernández-Avilés, C | 1 |
| Gallego, JJ | 1 |
| Castarlenas, L | 1 |
| Swanson, MS | 1 |
| de la Torre, R | 1 |
| Maldonado, R | 1 |
| Puig, MV | 1 |
| Robledo, P | 1 |
| Prihodova, I | 1 |
| Dudova, I | 1 |
| Mohaplova, M | 1 |
| Hrdlicka, M | 1 |
| Nevsimalova, S | 1 |
| Madjar, N | 1 |
| Shlosberg, D | 1 |
| Leventer-Roberts, M | 1 |
| Akriv, A | 1 |
| Ghilai, A | 1 |
| Hoshen, M | 1 |
| Krivoy, A | 1 |
| Zalsman, G | 1 |
| Shoval, G | 1 |
| Bruera, E | 3 |
| Yennurajalingam, S | 2 |
| Palmer, JL | 2 |
| Perez-Cruz, PE | 1 |
| Frisbee-Hume, S | 1 |
| Allo, JA | 1 |
| Williams, JL | 1 |
| Cohen, MZ | 1 |
| Parker, G | 1 |
| Brotchie, H | 1 |
| McClure, G | 1 |
| Fletcher, K | 1 |
| Gong, S | 1 |
| Sheng, P | 1 |
| Jin, H | 1 |
| He, H | 1 |
| Qi, E | 1 |
| Chen, W | 1 |
| Dong, Y | 1 |
| Hou, L | 1 |
| Kim, Y | 1 |
| Kim, B | 1 |
| Chang, JS | 1 |
| Kim, BN | 2 |
| Cho, SC | 2 |
| Hwang, JW | 1 |
| Rayner, L | 1 |
| Hotopf, M | 1 |
| Centeno, C | 2 |
| Sanz, A | 1 |
| Cuervo, MA | 1 |
| Ramos, D | 1 |
| Hernansanz, S | 1 |
| Gonzalez, J | 1 |
| Almaraz, MJ | 1 |
| Lama, M | 1 |
| Vara, F | 1 |
| Nabal, M | 1 |
| Pascual, A | 1 |
| Cubero-Millán, I | 2 |
| Molina-Carballo, A | 2 |
| Machado-Casas, I | 2 |
| Fernández-López, L | 2 |
| Martínez-Serrano, S | 2 |
| Tortosa-Pinto, P | 2 |
| Ruiz-López, A | 2 |
| Luna-del-Castillo, JD | 2 |
| Uberos, J | 2 |
| Muñoz-Hoyos, A | 2 |
| Rezaei, F | 1 |
| Emami, M | 1 |
| Zahed, S | 1 |
| Morabbi, MJ | 1 |
| Farahzadi, M | 1 |
| Akhondzadeh, S | 1 |
| Covey, LS | 1 |
| Hu, MC | 1 |
| Winhusen, T | 1 |
| Lima, J | 1 |
| Berlin, I | 1 |
| Nunes, E | 1 |
| Malhi, GS | 1 |
| Byrow, Y | 1 |
| Bassett, D | 1 |
| Boyce, P | 1 |
| Hopwood, M | 1 |
| Lyndon, W | 1 |
| Mulder, R | 1 |
| Porter, R | 1 |
| Singh, A | 1 |
| Murray, G | 1 |
| Sullivan, DR | 1 |
| Mongoue-Tchokote, S | 1 |
| Mori, M | 1 |
| Goy, E | 1 |
| Ganzini, L | 1 |
| Maksimowski, MB | 1 |
| Tampi, RR | 1 |
| Yohn, SE | 1 |
| Arif, Y | 1 |
| Haley, A | 1 |
| Tripodi, G | 1 |
| Baqi, Y | 1 |
| Müller, CE | 1 |
| Miguel, NS | 1 |
| Correa, M | 1 |
| Salamone, JD | 1 |
| Motaghinejad, M | 1 |
| Motevalian, M | 1 |
| Shabab, B | 1 |
| Fatima, S | 1 |
| Ruiz-Ramos, MJ | 1 |
| Ghanizadeh, A | 1 |
| Hardy, SE | 1 |
| Silver, JM | 1 |
| McAllister, TW | 1 |
| Arciniegas, DB | 1 |
| Spiegel, DR | 1 |
| Kim, J | 1 |
| Greene, K | 1 |
| Conner, C | 1 |
| Zamfir, D | 1 |
| Lasheen, W | 1 |
| Walsh, D | 1 |
| Mahmoud, F | 1 |
| Davis, MP | 1 |
| Rivera, N | 1 |
| Khoshknabi, DS | 1 |
| Shostrom, VK | 1 |
| Bhatia, SC | 1 |
| Wengel, SP | 1 |
| Potter, JF | 1 |
| Corchs, F | 1 |
| Teng, CT | 1 |
| Chacko, R | 1 |
| Portela, MA | 1 |
| Rubiales, AS | 1 |
| Prommer, E | 1 |
| Rickards, H | 1 |
| Cavanna, AE | 1 |
| Worrall, R | 1 |
| Kerr, CW | 1 |
| Drake, J | 1 |
| Milch, RA | 1 |
| Brazeau, DA | 1 |
| Skretny, JA | 1 |
| Brazeau, GA | 1 |
| Donnelly, JP | 1 |
| Lakić, A | 1 |
| Brookshire, BR | 1 |
| Jones, SR | 1 |
| Sánchez-Pérez, AM | 1 |
| García-Avilés, Á | 1 |
| Albert Gascó, H | 1 |
| Sanjuán, J | 1 |
| Olucha-Bordonau, FE | 1 |
| Kim, JW | 1 |
| Park, S | 1 |
| Shin, MS | 1 |
| Kim, JH | 1 |
| Son, JW | 1 |
| Shin, YM | 1 |
| Chung, US | 1 |
| Han, DH | 1 |
| Woolley, JB | 1 |
| Heyman, I | 1 |
| Kajs-Wyllie, M | 1 |
| DAVIDOFF, E | 1 |
| BEST, JL | 1 |
| MCPHEETERS, HL | 1 |
| FERRARA, FA | 1 |
| MORGAN, DR | 1 |
| BARISON, F | 1 |
| MASSIGNAN, L | 1 |
| ROBIN, AA | 1 |
| WISEBERG, S | 1 |
| TICKTIN, H | 1 |
| EPSTEIN, J | 1 |
| SHEA, JG | 1 |
| FAZEKAS, JF | 1 |
| WALTER, B | 1 |
| HOLZINGER, HH | 1 |
| VONDRACEK, V | 1 |
| DOBRY, J | 1 |
| DENZEL, HA | 1 |
| JACOBSON, A | 1 |
| BARTLET, JE | 1 |
| KOZLOWSKI, VL | 1 |
| FONTAN BALESTRA, E | 1 |
| KERENYI, AB | 1 |
| KORANYI, EK | 1 |
| SARWER-FONER, GJ | 1 |
| JAFFE, GV | 1 |
| WITTON, K | 2 |
| GARDE, A | 1 |
| SOURS, JA | 1 |
| SIEGLER, PE | 1 |
| LINKA, Z | 1 |
| POLLACK, B | 1 |
| FELLNER, CH | 1 |
| FERGUSON, JT | 1 |
| STIER, C | 1 |
| KOUTSKY, CD | 1 |
| WESTENDORP, F | 1 |
| BRANSFORD, P | 1 |
| Sharav, VH | 1 |
| Carlson, PJ | 1 |
| Merlock, MC | 1 |
| Suppes, T | 1 |
| Meyers, BJ | 1 |
| van Ojen, RL | 1 |
| Rikkert, MG | 1 |
| Geurts, AC | 1 |
| Lem, FC | 1 |
| Lee, H | 1 |
| Kim, SW | 1 |
| Kim, JM | 1 |
| Shin, IS | 1 |
| Yoon, JS | 1 |
| Rosenberg, M | 1 |
| Kratochvil, CJ | 1 |
| Varley, C | 1 |
| Cummins, TK | 1 |
| Martin, A | 1 |
| Lewis, JJ | 1 |
| Iezzoni, JC | 1 |
| Berg, CL | 1 |
| Yamada, S | 1 |
| Williams, LM | 1 |
| Hermens, DF | 1 |
| Palmer, D | 1 |
| Kohn, M | 1 |
| Clarke, S | 1 |
| Keage, H | 1 |
| Clark, CR | 1 |
| Gordon, E | 1 |
| Jones, SD | 1 |
| Whalen, CK | 1 |
| Henker, B | 1 |
| Reisberg, B | 1 |
| Ferris, SH | 1 |
| Gershon, S | 1 |
| Moore, DP | 1 |
| Branconnier, RJ | 1 |
| Cole, JO | 1 |
| Klein, DF | 1 |
| Katon, W | 1 |
| Raskind, M | 1 |
| Grizenko, N | 1 |
| Pawliuk, N | 1 |
| Block, RW | 1 |
| Feeney, DJ | 1 |
| Klykylo, WM | 1 |
| Frye, CB | 1 |
| Grade, C | 1 |
| Redford, B | 1 |
| Chrostowski, J | 1 |
| Toussaint, L | 1 |
| Blackwell, B | 1 |
| Challman, TD | 1 |
| Lipsky, JJ | 1 |
| Pereira, J | 1 |
| Jansen, IH | 1 |
| Olde Rikkert, MG | 1 |
| Hulsbos, HA | 1 |
| Hoefnagels, WH | 1 |
| Weisfelt, M | 1 |
| Schrier, AC | 1 |
| de Leeuw, MC | 1 |
| Rozans, M | 1 |
| Dreisbach, A | 1 |
| Lertora, JJ | 1 |
| Kahn, MJ | 1 |
| Krupp, LB | 1 |
| Christodoulou, C | 1 |
| Liebelt, EL | 1 |
| Gadow, KD | 1 |
| Nolan, EE | 1 |
| Sverd, J | 1 |
| Sprafkin, J | 1 |
| Schwartz, J | 1 |
| LeGrand, SB | 1 |
| Kadouch, R | 1 |
| Belmaker, RH | 1 |
| Ebstein, RP | 1 |
| Peres, L | 1 |
| Denber, HC | 1 |
| Gualtieri, CT | 1 |
| Smith, RC | 1 |
| Davis, JM | 1 |
| Huapaya, LV | 1 |
| Bloomingdale, LM | 1 |
| Bressler, B | 1 |
| Rosenfeld, AA | 1 |
| Wood, DR | 1 |
| Reimherr, FW | 1 |
| Wender, PH | 1 |
| Johnson, GE | 1 |
| Brumback, RA | 1 |
| Weinberg, WA | 1 |
| Renshaw, D | 1 |
| Leichner, PP | 1 |
| Janowsky, DS | 1 |
| Reid, AE | 1 |
| Elmore, JL | 1 |
| Sugerman, AA | 1 |
| Shader, RI | 1 |
| Naor, S | 1 |
| Talmon, Y | 1 |
| Guy, N | 1 |
| Levenson, JA | 1 |
| Alston, CY | 1 |
| Romney, DM | 1 |
| Gerner, RH | 1 |
| Woods, SW | 1 |
| Tesar, GE | 1 |
| Murray, GB | 1 |
| Cassem, NH | 1 |
| McNair, DM | 1 |
| Rosen, S | 1 |
| Martorano, J | 1 |
| Guilleminault, C | 1 |
| Carskadon, M | 1 |
| Dement, WC | 1 |
| Sutter, JM | 1 |
| Debrie, ML | 1 |
| Luccioni, H | 1 |
| Scotto, JC | 1 |
| Begarra, R | 1 |
| Ney, PG | 1 |
| Ananth, J | 1 |
| Ruskin, R | 1 |
| Glassman, AH | 1 |
| Perel, JM | 3 |
| Gilbert, JG | 1 |
| Donnelly, KJ | 1 |
| Zimmer, LE | 1 |
| Kubis, JF | 1 |
| Cooper, TB | 1 |
| Simpson, GM | 1 |
| Rickels, K | 1 |
| Downing, RW | 1 |
| Lipman, RS | 1 |
| Fisher, E | 1 |
| Randall, AM | 1 |
| Falk, MA | 1 |
| Wharton, RN | 2 |
| Dayton, PG | 1 |
| Malitz, S | 2 |
| Robie, TR | 1 |
| Meyer, JS | 1 |
| Eadie, GA | 1 |
| Ericsson, AD | 1 |
| Hoobler, SW | 1 |
| MacMahon, HR | 1 |
| Rapp, MS | 1 |
| Zeidenberg, P | 1 |
| Kanzler, M | 1 |
| Bojanovský, J | 1 |
| Chloupková, K | 1 |
| McNair, FE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood[NCT00550667] | 1,120 participants (Actual) | Observational | 2007-10-01 | Completed | |||
| Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study[NCT00495820] | Phase 4 | 60 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924] | 42 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| A Randomized Controlled Trial of Methylphenidate and a Nursing Telephone Intervention (NTI) for Fatigue in Advanced Cancer Patients[NCT00424099] | Phase 2/Phase 3 | 197 participants (Actual) | Interventional | 2007-01-09 | Completed | ||
| A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers With ADHD[NCT00253747] | Phase 3 | 255 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| Exercise Training in Depressed Traumatic Brain Injury Survivors[NCT01805479] | 0 participants (Actual) | Interventional | 2013-02-28 | Withdrawn (stopped due to Unable to enroll participants. Sponsor requested study closure.) | |||
| A Randomized Placebo-controlled Trial of Methylphenidate in Veterans With a Diagnosis of Post Traumatic Stress Disorder and Recent Cerebral Stroke.[NCT04885257] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-01-14 | Recruiting | ||
| Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction[NCT02386475] | Phase 4 | 39 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Methylphenidate Effect on Performing Humphrey Visual Fields[NCT02162381] | 32 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| A Parallel-group, Double-blind, Placebo-controlled Study of Methylphenidate as an Add on Therapy for Mirtazapine in the Treatment of Major Depressive Disorder in Cancer Patients Under Palliative Care[NCT01497548] | Phase 3 | 120 participants (Anticipated) | Interventional | 2011-03-31 | Recruiting | ||
| Randomized Study Evaluating the Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients[NCT00273741] | Phase 3 | 39 participants (Actual) | Interventional | 2007-01-31 | Terminated (stopped due to difficulty of recrutement) | ||
| Treatment Study for Frontotemporal Dementia[NCT00088751] | 20 participants | Observational | 2004-07-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Apathy Evaluation Scale (AES) has been specifically developed to assess apathy and discriminate it from depression. This 18 item scale with score ranging from 18 to 72, assesses apathy in behavioral, cognitive and emotional domains over the previous four weeks. Higher scores indicate worsening apathy. (NCT00495820)
Timeframe: At 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Methylphenidate Group | 38.2 |
| Placebo Group | 43.6 |
The Clinical Global Impression scale is an observational scale of global evaluation, which assesses the change in degree of illness in relation to the original assessment. The severity sub-scale reported below ranges from 1-7 wherein higher scores indicate worsening severity of illness. (NCT00495820)
Timeframe: At 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Methylphenidate Group | 3.9 |
| Placebo Group | 4.8 |
Mini-mental State Examination (MMSE) is a commonly used screening measure for cognition with questions pertaining to orientation, registration, recall, visuo-spatial construction, attention span etc. Score on MMSE ranges from 0-30, higher scores indicating improving cognition (NCT00495820)
Timeframe: At 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Methylphenidate Group | 25.8 |
| Placebo Group | 23.6 |
The ESAS was used to assess the following 9 symptoms commonly experienced symptoms by cancer patients: pain, fatigue, nausea, depression, anxiety, drowsiness, dyspnea, anorexia, and well-being. Patients rate the intensity of their fatigue symptoms on a scale of 0 to 10 (0=not at all and 10=very much). Total ESAS fatigue score ranges from 0 to 10 with higher scores indicate higher fatigue. We measured the median change in ESAS fatigue score between Baseline and Day 15 using Kruskal-Wallis test. (NCT00424099)
Timeframe: Baseline and Day 15
| Intervention | score on a scale (Median) |
|---|---|
| Methylphenidate (MP) + Nursing Telephone Intervention (NTI) | -3.00 |
| Methylphenidate (MP) + Control Telephone Intervention (CTI) | -1.00 |
| Placebo (PL)+ Nursing Telephone Intervention (NTI) | -2.00 |
| Placebo (PL) + Control Telephone Intervention (CTI) | -2.00 |
FACIT-F fatigue subscale consists of 13 items. Patients rate the intensity of their fatigue symptoms on a scale of 0 to 4 (0=not at all and 4=very much). Total FACIT-F fatigue subscale score ranges from 0 to 52 with higher scores indicate higher fatigue. We measured the median change in FACIT-F fatigue sub scale score between Baseline and Day 15 using Kruskal-Wallis test. (NCT00424099)
Timeframe: Baseline and Day 15
| Intervention | score on a scale (Median) |
|---|---|
| Methylphenidate (MP) + Nursing Telephone Intervention (NTI) | 4.00 |
| Methylphenidate (MP) + Control Telephone Intervention (CTI) | 7.00 |
| Placebo (PL)+ Nursing Telephone Intervention (NTI) | 8.50 |
| Placebo (PL) + Control Telephone Intervention (CTI) | 5.00 |
A Generalized Estimating Equations(GEE)model which included treatment group, week, site, and treatment by week and site by week interaction effects was used to compare the groups on the DSM-IV ADHD total severity score (18 domains score at severity levels of 0[none]-3[severe]; maximum score 54) as measured at screening/baseline and study weeks 1-4 using the the interviewer-administered DSM-IV checklist and by the severity portion of the National Institute of Mental Health Clinical Global Impression (CGI) scale to rate the severity of the participant's ADHD symptoms. A single severity score ranging from 1 to 7 is yielded by the CGI severity scale. (NCT00253747)
Timeframe: Baseline and Study weeks 1,4,7,9,11
| Intervention | DSM IV ADHD Score (Mean) |
|---|---|
| Osmotic-Release Methylphenidate (OROS-MPH)-Baseline | 38.4 |
| Osmotic-Release Methylphenidate (OROS-MPH) - Placebo-Baseline | 36.6 |
| Osmotic-Release Methylphenidate (OROS-MPH)-Week 11 | 16.4 |
| Osmotic-Release Methylphenidate (OROS-MPH) - Placebo-Week 11 | 24.2 |
| Release Methylphenidate (OROS-MPH)-Week 4 | 20.4 |
| Osmotic-Release Methylphenidate (OROS-MPH) - Placebo-Week 4 | 27.2 |
| Release Methylphenidate (OROS-MPH)-Week 7 | 20 |
| Osmotic-Release Methylphenidate (OROS-MPH) - Placebo-Week 7 | 24 |
| Release Methylphenidate (OROS-MPH)-Week 9 | 17.3 |
| Methylphenidate (OROS-MPH) - Placebo-Week 9 | 23.9 |
A logistic regression including site and treatment group will be used to model rates of achieving point prevalence abstinence as assessed at the final visit of the O-MPH/P-Stnd Smoking Tx phase. Point prevalence abstinence was defined as not smoking in the previous seven days based on self-report using the TLFB method and confirmed with a Carbon Monoxide (CO) level <8 ppm. (NCT00253747)
Timeframe: Week 11
| Intervention | participants (Number) |
|---|---|
| Osmotic-Release Methylphenidate (OROS-MPH) | 24 |
| Osmotic-Release Methylphenidate (OROS-MPH) - Placebo | 26 |
"The smoking quit date was considered the first day of the O-MPH/P-Stnd Smoking Tx phase, which lasted for 6 weeks or more precisely 42 days (i.e., approximately weeks 5-10). The grace period was the first two weeks (i.e., days 1-14) with the remaining four weeks (days 15-42) comprising the period in which the participant must not meet criteria for treatment failure in order to be scored as obtaining prolonged abstinence. Self-report of cigarette use was assessed using a time-line follow-back (TLFB) assessment using carbon monoxide (CO)levels to correct self-reported smoking days. Smoking days were determined by starting with self-reported smoking and non-smoking days and using CO levels measured at weekly visits to modify the self-reports." (NCT00253747)
Timeframe: Weeks 7-10
| Intervention | participants (Number) |
|---|---|
| Osmotic-Release Methylphenidate (OROS-MPH) | 25 |
| Osmotic-Release Methylphenidate (OROS-MPH) - Placebo | 28 |
28 reviews available for methylphenidate and Depression
| Article | Year |
|---|---|
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Attention Deficit Disorder with Hyperactiv | 2021 |
Therapeutic benefits of pharmacologic and nonpharmacologic treatments for depressive symptoms after traumatic brain injury: a systematic review and network meta-analysis.
Topics: Brain Injuries, Traumatic; Depression; Depressive Disorder, Major; Humans; Methylphenidate; Network | 2021 |
Methylphenidate use in geriatric depression: A systematic review.
Topics: Aged; Citalopram; Depression; Depressive Disorder, Major; Humans; Methylphenidate; Middle Aged; Pros | 2021 |
Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis.
Topics: Adult; Central Nervous System Stimulants; Depression; Fatigue; Humans; Methylphenidate; Network Meta | 2021 |
The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review.
Topics: Analgesics, Opioid; Animals; Cancer Pain; Central Nervous System Stimulants; Cognitive Dysfunction; | 2018 |
[Apathetic geriatric patient benefits from methylphenidate].
Topics: Aged; Aged, 80 and over; Aging; Apathy; Dementia; Depression; Female; Humans; Male; Methylphenidate; | 2017 |
[Psychostimulants for late life depression].
Topics: Aged; Aged, 80 and over; Central Nervous System Stimulants; Depression; Humans; Methylphenidate; Mid | 2018 |
Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis.
Topics: Cognition; Depression; Fatigue; Humans; Methylphenidate; Neoplasms | 2014 |
Stimulants for depression: On the up and up?
Topics: Amphetamine; Antidepressive Agents; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System S | 2016 |
Efficacy of stimulants for psychiatric symptoms in individuals with traumatic brain injury.
Topics: Brain Injuries, Traumatic; Central Nervous System Stimulants; Depression; Humans; Methylphenidate; R | 2016 |
Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Chronic Disease; Clinical Trials as Topic; Depressio | 2009 |
Depression and cognitive complaints following mild traumatic brain injury.
Topics: Antidepressive Agents, Tricyclic; Brain; Brain Injuries; Central Nervous System Stimulants; Choline; | 2009 |
The use of psychostimulants in cancer patients.
Topics: Adult; Antineoplastic Agents; Asthenia; Benzhydryl Compounds; Central Nervous System Stimulants; Chi | 2011 |
Methylphenidate: established and expanding roles in symptom management.
Topics: Analgesics, Opioid; Brain Neoplasms; Central Nervous System Stimulants; Cognition; Cognition Disorde | 2012 |
[Effects of methylphenidate on anxiety].
Topics: Adolescent; Adult; Age Factors; Animals; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Attention | 2012 |
Ritalin revisited: does it really help in neurological injury?
Topics: Attention Deficit Disorder with Hyperactivity; Brain Injuries; Brain Neoplasms; Central Nervous Syst | 2002 |
NARCOLEPSY AND OTHER DISTURBANCES IN THE SLEEP-WAKING RHYTHM: A STUDY OF 115 CASES WITH REVIEW OF THE LITERATURE.
Topics: Black People; Cataplexy; Craniocerebral Trauma; Depression; Dextroamphetamine; Encephalitis; Halluci | 1963 |
CURRENT STATUS OF DRUG TREATMENT IN THE DEPRESSIVE STATE.
Topics: Amitriptyline; Amphetamine; Amphetamines; Antidepressive Agents; Aspartic Acid; Benactyzine; Classif | 1964 |
[Pharmacologic treatment of Asperger syndrome].
Topics: Aggression; Antidepressive Agents, Second-Generation; Asperger Syndrome; Child; Communication; Depre | 2007 |
Pharmacotherapy of senile dementia.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Amphetamine; Antidepressive Agents, Tricyclic; Dementia | 1980 |
Methylphenidate: its pharmacology and uses.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Nervous System Stimulants; De | 2000 |
Methylphenidate: its pharmacology and uses.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Nervous System Stimulants; De | 2000 |
Methylphenidate: its pharmacology and uses.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Nervous System Stimulants; De | 2000 |
Methylphenidate: its pharmacology and uses.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Nervous System Stimulants; De | 2000 |
[Hyperactive behavior in adults; possibly attention deficit/hyperactivity disorder (ADHD)].
Topics: Adult; Alcoholism; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2001 |
Palliative uses of methylphenidate in patients with cancer: a review.
Topics: Analgesics, Opioid; Central Nervous System Stimulants; Cognition Disorders; Depression; Disorders of | 2002 |
Palliative uses of methylphenidate in patients with cancer: a review.
Topics: Analgesics, Opioid; Central Nervous System Stimulants; Cognition Disorders; Depression; Disorders of | 2002 |
Palliative uses of methylphenidate in patients with cancer: a review.
Topics: Analgesics, Opioid; Central Nervous System Stimulants; Cognition Disorders; Depression; Disorders of | 2002 |
Palliative uses of methylphenidate in patients with cancer: a review.
Topics: Analgesics, Opioid; Central Nervous System Stimulants; Cognition Disorders; Depression; Disorders of | 2002 |
Fatigue in multiple sclerosis.
Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste | 2001 |
Use, abuse, toxicity, and monitoring of pediatric psychotropic drug therapy: new issues for the new millennium.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Depression; | 2002 |
Present status of drug therapy of depression in late life.
Topics: Age Factors; Aged; Antidepressive Agents; Antipsychotic Agents; Depression; Humans; Kinetics; Lithiu | 1985 |
Self-evaluations of antidepressants.
Topics: Amitriptyline; Antidepressive Agents; Chlordiazepoxide; Clinical Trials as Topic; Depression; Desipr | 1974 |
The clinical pharmacology of imipramine. Implications for therapeutics.
Topics: Administration, Oral; Barbiturates; Cell Membrane Permeability; Depression; Desipramine; Drug Intera | 1973 |
24 trials available for methylphenidate and Depression
| Article | Year |
|---|---|
Differentiating depression and ADHD without depression in adults with processing-speed measures.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2020 |
The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder.
Topics: Adolescent; Anxiety; Asperger Syndrome; Attention Deficit Disorder with Hyperactivity; Central Nervo | 2017 |
Efficacy of methylphenidate for the treatment of mental sequelae after traumatic brain injury.
Topics: Adult; Brain Injuries, Traumatic; Cognition Disorders; Depression; Double-Blind Method; Female; Huma | 2017 |
Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Apathy; Caregivers; Central | 2018 |
Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial.
Topics: Administration, Oral; Adult; Aged; Central Nervous System Stimulants; Counseling; Depression; Dopami | 2013 |
Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial.
Topics: Administration, Oral; Adult; Aged; Central Nervous System Stimulants; Counseling; Depression; Dopami | 2013 |
Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial.
Topics: Administration, Oral; Adult; Aged; Central Nervous System Stimulants; Counseling; Depression; Dopami | 2013 |
Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial.
Topics: Administration, Oral; Adult; Aged; Central Nervous System Stimulants; Counseling; Depression; Dopami | 2013 |
Multicentre, double-blind, randomised placebo-controlled clinical trial on the efficacy of methylphenidate on depressive symptoms in advanced cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Central Nervous System Stimulants; Depression; Double-Blind Method; | 2012 |
Methylphenidate ameliorates depressive comorbidity in ADHD children without any modification on differences in serum melatonin concentration between ADHD subtypes.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2014 |
Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial.
Topics: Adult; Amphetamine-Related Disorders; Craving; Delayed-Action Preparations; Depression; Double-Blind | 2015 |
Randomized, double-blind, placebo-controlled study of methylphenidate for the treatment of depression in SSRI-treated cancer patients receiving palliative care.
Topics: Adult; Aged; Central Nervous System Stimulants; Depression; Double-Blind Method; Female; Hospice Car | 2017 |
Methylphenidate for apathy and functional status in dementia of the Alzheimer type.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Central Nervous System Stimulants; Depression; | 2010 |
Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Central Nervous System Stimulants; Depression; Double-Blind Method; Fatigue | 2012 |
Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation.
Topics: Adult; Aged; Amphetamine; Antipsychotic Agents; Bipolar Disorder; Central Nervous System Stimulants; | 2004 |
Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury.
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Cognition Disorders; Depression; Do | 2005 |
Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury.
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Cognition Disorders; Depression; Do | 2005 |
Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury.
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Cognition Disorders; Depression; Do | 2005 |
Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury.
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Cognition Disorders; Depression; Do | 2005 |
Misinterpreting emotional expressions in attention-deficit/hyperactivity disorder: evidence for a neural marker and stimulant effects.
Topics: Adolescent; Anxiety; Attention Deficit Disorder with Hyperactivity; Brain Mapping; Case-Control Stud | 2008 |
Methylphenidate in depression and states of apathy.
Topics: Clinical Trials as Topic; Depression; Double-Blind Method; Humans; Methylphenidate; Mood Disorders | 1981 |
Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study.
Topics: Activities of Daily Living; Adaptation, Psychological; Aged; Central Nervous System Stimulants; Cere | 1998 |
Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study.
Topics: Activities of Daily Living; Adaptation, Psychological; Aged; Central Nervous System Stimulants; Cere | 1998 |
Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study.
Topics: Activities of Daily Living; Adaptation, Psychological; Aged; Central Nervous System Stimulants; Cere | 1998 |
Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study.
Topics: Activities of Daily Living; Adaptation, Psychological; Aged; Central Nervous System Stimulants; Cere | 1998 |
Toward individualized evidence-based medicine: five "N of 1" trials of methylphenidate in geriatric patients.
Topics: Aged; Aged, 80 and over; Cross-Over Studies; Depression; Double-Blind Method; Drug Evaluation; Evide | 2001 |
Anxiety and depression symptoms and response to methylphenidate in children with attention-deficit hyperactivity disorder and tic disorder.
Topics: Adolescent; Analysis of Variance; Anxiety; Attention Deficit Disorder with Hyperactivity; Central Ne | 2002 |
Comparative effects of d-amphetamine, l-amphetamine, and methylphenidate on mood in man.
Topics: Adult; Amphetamines; Depression; Dextroamphetamine; Double-Blind Method; Emotions; Euphoria; Female; | 1977 |
Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report.
Topics: Adult; Alcoholism; Antisocial Personality Disorder; Anxiety; Attention Deficit Disorder with Hyperac | 1976 |
Self-evaluations of antidepressants.
Topics: Amitriptyline; Antidepressive Agents; Chlordiazepoxide; Clinical Trials as Topic; Depression; Desipr | 1974 |
[Role of fatigue in depressive states; its modification by the action of a psychotonic agent].
Topics: Antidepressive Agents; Depression; Dibenzazepines; Evaluation Studies as Topic; Humans; Mental Fatig | 1972 |
Effect of magnesium pemoline and methylphenidate on memory improvement and mood in normal aging subjects.
Topics: Affect; Aged; Anxiety; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Depression; | 1973 |
A pilot study of antihypertensive therapy in cerebrovascular disease.
Topics: Adult; Cerebrovascular Disorders; Clinical Trials as Topic; Depression; Female; Humans; Hypertension | 1967 |
94 other studies available for methylphenidate and Depression
| Article | Year |
|---|---|
Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit/hyperactivity disorder with comorbid depression:
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cohort | 2023 |
The use of stimulants in depression: Results from a self-controlled register study.
Topics: Adult; Amphetamine; Central Nervous System Stimulants; Denmark; Depression; Dextroamphetamine; Drug | 2020 |
Relief of Pain-Depressed Behavior in Rats by Activation of D1-Like Dopamine Receptors.
Topics: Analgesics; Animals; Behavior, Animal; Benzazepines; Conditioning, Operant; Depression; Dopamine Ago | 2017 |
Methylphenidate Attenuates the Cognitive and Mood Alterations Observed in Mbnl2 Knockout Mice and Reduces Microglia Overexpression.
Topics: Affect; Animals; Brain; Central Nervous System Stimulants; Cognition; Cognitive Dysfunction; Depress | 2019 |
Childhood narcolepsy and autism spectrum disorders: four case reports.
Topics: Age of Onset; Antidepressive Agents; Anxiety Disorders; Asperger Syndrome; Attention Deficit Disorde | 2018 |
Childhood methylphenidate adherence as a predictor of antidepressants use during adolescence.
Topics: Antidepressive Agents; Central Nervous System Stimulants; Child; Cohort Studies; Depression; Female; | 2019 |
Psychostimulants for managing unipolar and bipolar treatment-resistant melancholic depression: a medium-term evaluation of cost benefits.
Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Central Nervous System Stimulants; Cost-Benefit An | 2013 |
Parental quality of life and depressive mood following methylphenidate treatment of children with attention-deficit hyperactivity disorder.
Topics: Adolescent; Adult; Affect; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2014 |
Better--but good enough? The first randomised controlled trial of psychostimulants for depressive symptoms in advanced cancer.
Topics: Central Nervous System Stimulants; Depression; Female; Humans; Male; Methylphenidate; Neoplasms | 2012 |
Anxiety and Depressed Mood Decline Following Smoking Abstinence in Adult Smokers with Attention Deficit Hyperactivity Disorder.
Topics: Adult; Anxiety; Attention Deficit Disorder with Hyperactivity; Combined Modality Therapy; Counseling | 2015 |
Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Central Nervous System Stimulants; Cho | 2016 |
Effects of acute doses of methylphenidate on inflammation and oxidative stress in isolated hippocampus and cerebral cortex of adult rats.
Topics: Animals; Anxiety; Cerebral Cortex; Depression; Dose-Response Relationship, Drug; Hippocampus; Inflam | 2017 |
BDNF concentrations and daily fluctuations differ among ADHD children and respond differently to methylphenidate with no relationship with depressive symptomatology.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Biomarkers; Brain-Derived Neurotrophic Fa | 2017 |
Insomnia, night terror, and depression related to clonidine in attention-deficit/hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2008 |
Apathy due to cerebrovascular accidents successfully treated with methylphenidate: a case series.
Topics: Aged; Depression; Humans; Male; Methylphenidate; Middle Aged; Mood Disorders; Motivation; Stroke; Tr | 2009 |
Methylphenidate side effects in advanced cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Akathisia, Drug-Induced; Anorexia; Central Nervous System Stimulants | 2010 |
Amphetamine, catatonic depression, and heart transplant: a case report.
Topics: Catatonia; Central Nervous System Stimulants; Depression; Heart Transplantation; Humans; Male; Methy | 2010 |
Factors associated with response to methylphenidate in advanced cancer patients.
Topics: Anorexia; Anxiety; Central Nervous System Stimulants; Depression; Drug Monitoring; Dyspnea; Fatigue; | 2011 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride | 2012 |
Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2012 |
Chronic methylphenidate administration in mice produces depressive-like behaviors and altered responses to fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Drug Administration Schedule; Female; | 2012 |
Parental perceived benefits of OROS-methylphenidate treatment for the child with attention-deficit/hyperactivity disorder and for parents themselves.
Topics: Adult; Asian People; Attention; Attention Deficit Disorder with Hyperactivity; Caregivers; Central N | 2013 |
Dexamphetamine for obsessive-compulsive disorder.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2003 |
The effect of ritalin (methyl-phenidylacetate hydrochloride) on mildly depressed ambulatory patients.
Topics: Depression; Depressive Disorder; Methylphenidate; Salts | 1957 |
[Ritalin & Rauwolfia & its alkaloids].
Topics: Alkaloids; Antihypertensive Agents; Depression; Depressive Disorder; Humans; Hypnotics and Sedatives | 1956 |
Largactil, ritalin and meratran in the treatment of endogenous psychotic depression.
Topics: Bipolar Disorder; Chlorpromazine; Depression; Depressive Disorder, Major; Methylphenidate; Piperidin | 1957 |
[Observations on neurotic depressions with reference to a combined serpasil-ritalin treatment].
Topics: Combined Modality Therapy; Depression; Depressive Disorder; Manipulation, Osteopathic; Methylphenida | 1956 |
A controlled trial of methyl phenidate (ritalin) in the treatment of depressive states.
Topics: Depression; Depressive Disorder; Methylphenidate | 1958 |
Effect of methylphenidate hydrochloride in antagonizing barbiturate-induced depression.
Topics: Barbiturates; Depression; Depressive Disorder; Methylphenidate | 1958 |
[Influencing of depressive states in geriatrics].
Topics: Aged; Depression; Depressive Disorder; Geriatrics; Methylphenidate; Reserpine | 1958 |
[Ritalin, a new psychotomimetic].
Topics: Depression; Depressive Disorder; Methylphenidate | 1958 |
Clinical trial of ritalin in the treatment of chronically underactive and depressed patients.
Topics: Depression; Electroencephalography; Methylphenidate; Movement Disorders | 1958 |
The use of ritalin in psychotherapy of depressions of the aged.
Topics: Aged; Depression; Depressive Disorder; Humans; Methylphenidate; Psychotherapy | 1958 |
Place of methyl phenidate hydrochloride in psychiatric practice.
Topics: Depression; Depressive Disorder; Methylphenidate; Reserpine; Salts | 1959 |
Depressive symptoms.
Topics: Depression; Depressive Disorder; Electroconvulsive Therapy; Mental Disorders; Methylphenidate; Psych | 1959 |
[Asthma and depression. Treatment with methylphenidylacetate].
Topics: Asthma; Depression; Depressive Disorder; Methylphenidate | 1961 |
Depressive states and drugs. III. Use of methylphenidate (Ritalin) in open psychiatric settings and in office practice.
Topics: Depression; Depressive Disorder; Methylphenidate | 1960 |
Depression in general practice. A clinical trial of a new psychomotor stimulant.
Topics: Depression; Depressive Disorder; Family Practice; General Practice; Methylphenidate | 1961 |
Clinical observations on ritalin HCl (methylphenidylacetate) injectable, multiple dose vial.
Topics: Depression; Depressive Disorder; Methylphenidate | 1960 |
[Results obtained with R.P. 8228 after 2 years of use of this psychotonic].
Topics: Depression; Depressive Disorder; Health Services; Methylphenidate; Sleep Wake Disorders | 1962 |
[CENTEDRIN THERAPY OF NEUROSES AMONG ADOLESCENTS].
Topics: Adolescent; Depression; Depressive Disorder; Drug Therapy; Enuresis; Humans; Methylphenidate; Neurot | 1964 |
REPORT OF AN UNUSUALLY LARGE DOSAGE OF METHYLPHENIDATE HYDROCHLORIDE.
Topics: Alcoholic Beverages; Benactyzine; Depression; Depressive Disorder; Imipramine; Meprobamate; Methylph | 1964 |
EARLY RECOGNITION OF DEPRESSION.
Topics: Amitriptyline; Amphetamine; Amphetamines; Barbiturates; Benactyzine; Chlordiazepoxide; Deanol; Depre | 1964 |
ON THE USE OF PARENTERAL METHYLPHENIDATE: A FOLLOW-UP REPORT.
Topics: Depression; Depressive Disorder; Drug Therapy; Follow-Up Studies; Injections; Injections, Intramuscu | 1964 |
Treatment of reserpine-induced depression with a new analeptic: phenidylate.
Topics: Central Nervous System Stimulants; Depression; Depressive Disorder; Mental Disorders; Methylphenidat | 1955 |
[The use of ritalin, a stimulant of the central nervous system, in depressive states and for the support of electric shock therapy].
Topics: Central Nervous System Agents; Central Nervous System Stimulants; Depression; Depressive Disorder; E | 1955 |
High dosage methylphenidate for depression.
Topics: Depression; Depressive Disorder; Methylphenidate | 1960 |
Children in clinical research: a conflict of moral values.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Control; Biomedical Research; Ch | 2003 |
[The treatment with methylphenidate of demoralisation, apathy and hypoactive delirium in patients with somatic illness].
Topics: Adult; Aged; Central Nervous System Stimulants; Delirium; Depression; Female; Humans; Lymphoma, B-Ce | 2004 |
[The treatment with methylphenidate of demoralisation, apathy and hypoactive delirium in patients with somatic illness].
Topics: Central Nervous System Stimulants; Clinical Trials as Topic; Delirium; Depression; Diagnosis, Differ | 2004 |
[The treatment with methylphenidate of demoralisation, apathy and hypoactive delirium in patients with somatic illness].
Topics: Central Nervous System Stimulants; Delirium; Depression; Humans; Methylphenidate; Somatoform Disorde | 2004 |
Mental illness and addiction issue brief: psychotropic medication and children: year end report-2004.
Topics: Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2004 |
Less is more: inpatient management of a child with complex pharmacotherapy.
Topics: Aggression; Amphetamines; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Depressio | 2006 |
Methylphenidate-induced autoimmune hepatitis.
Topics: Alanine Transaminase; Anti-Inflammatory Agents; Aspartate Aminotransferases; Bilirubin; Central Nerv | 2007 |
Treatment of depression.
Topics: Depression; Dextroamphetamine; Female; Humans; Methylphenidate | 1983 |
Hyperactivity and the attention deficit disorders: expanding frontiers.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Cognition; Cogni | 1984 |
The therapeutic role of methylphenidate in senile organic brain syndrome.
Topics: Aged; Anxiety; Confusion; Dementia; Depression; Double-Blind Method; Electroencephalography; Factor | 1980 |
Clinical and biological aspects of depression in the elderly.
Topics: Aged; Dementia; Depression; Doxepin; Humans; Imipramine; Methylphenidate; Middle Aged; Trazodone | 1980 |
Treatment of depression in the medically ill elderly with methylphenidate.
Topics: Adjustment Disorders; Aged; Antidepressive Agents, Tricyclic; Depression; Dose-Response Relationship | 1980 |
Depression and hopelessness in children with disruptive behaviour disorders.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child Behavior Disorders; Co | 1994 |
Medication for attention-deficit hyperactivity disorder: balancing art and science.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Agents; Depression | 1996 |
Medication-induced seizures.
Topics: 1-Naphthylamine; Adolescent; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; C | 1997 |
Methylphenidate for depression in the elderly, medically ill patient.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Central Nervous System Stimulants; Chronic Disease; | 1997 |
Depression with psychomotor retardation: diagnostic challenges and the use of psychostimulants.
Topics: Aged; Central Nervous System Stimulants; Depression; Humans; Male; Methylphenidate; Palliative Care; | 2001 |
Cancer fatigue--more data, less information?
Topics: Anemia; Central Nervous System Stimulants; Chronic Disease; Cytokines; Depression; Exercise; Fatigue | 2002 |
Thphenidate.
Topics: Adjustment Disorders; Adrenergic beta-Agonists; Adult; Bipolar Disorder; Blood Pressure; Cyclic AMP; | 1977 |
The pharmacologic treatment of depression.
Topics: Amphetamine; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Deanol; De | 1979 |
Imipramine and children: a review and some speculations about the mechanism of drug action.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Depression; Dopamine; Enuresis; Epilepsy, Absence; | 1977 |
Seven cases of somnambulism induced by drugs.
Topics: Adult; Alcoholism; Amitriptyline; Chlorprothixene; Depression; Drug Therapy, Combination; Ethchlorvy | 1979 |
Rapid intramuscular administration of tricyclic antidepressants.
Topics: Adjustment Disorders; Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depr | 1979 |
Depression and psychotic regression following prolonged methylphenidate use and withdrawal: case report.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Depression; Humans; Male; Methylphenidate; Psy | 1979 |
Childhood depression: an explanation of a behavior disorder of children.
Topics: Antidepressive Agents, Tricyclic; Bipolar Disorder; Child; Child Behavior Disorders; Depression; Dex | 1977 |
Comprehensive management of the hyperkinetic child.
Topics: Adolescent; Amphetamines; Anxiety; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; | 1976 |
Intravenous methylphenidate as a diagnostic and psychotherapeutic instrument in adult psychiatry.
Topics: Abreaction; Adult; Alcoholism; Antisocial Personality Disorder; Anxiety; Defense Mechanisms; Depress | 1976 |
Precipitation of psychosis during electroshock therapy.
Topics: Adult; Chlorpromazine; Depression; Diagnosis, Differential; Drug Therapy, Combination; Electroconvul | 1975 |
Problems of polypharmacy in depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Drug Therapy, Combination; Huma | 1976 |
[Combined tricyclic antidepressants and ritalin in elderly depressives].
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Drug Therapy, Combination; Female; Humans; Male; | 1992 |
Should psychostimulants be used to treat delirious patients with depressed mood?
Topics: Delirium; Depression; Depressive Disorder; Humans; Methylphenidate | 1992 |
A comparison of medicated and nonmedicated attention-deficit disordered hyperactive boys.
Topics: Achievement; Adolescent; Affect; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; | 1992 |
Psychostimulant treatment of depressive disorders secondary to medical illness.
Topics: Adjustment Disorders; Adult; Aged; Dementia; Depression; Depressive Disorder; Dextroamphetamine; Fem | 1986 |
Clinical application of antidepressant agents in disabled and rehabilitation patients.
Topics: Aged; Amitriptyline; Amphetamine; Antidepressive Agents; Depression; Disabled Persons; Hemiplegia; H | 1965 |
On the treatment of rapid eye movement narcolepsy.
Topics: Adult; Amphetamine; Antidepressive Agents; Cataplexy; Depression; Desipramine; Electroencephalograph | 1974 |
Four types of hyperkinesis.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child Abuse; Child Behavior | 1974 |
Treatment of intractable depression.
Topics: Amantadine; Antidepressive Agents; Depression; Dextroamphetamine; Drug Therapy, Combination; Hormone | 1974 |
Concomitant imipramine and methylphenidate administration: a case report.
Topics: Depression; Drug Synergism; Humans; Imipramine; Male; Methylphenidate; Middle Aged; Remission, Spont | 1973 |
The self-rating depression scale (SDS) as a measure of psychotropic drug response.
Topics: Adult; Amitriptyline; Anxiety; Chlordiazepoxide; Depression; Factor Analysis, Statistical; Female; H | 1973 |
Treatment of the depressed outpatient.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Anxiety; Child; Chlordiazepoxide; Dep | 1974 |
A potential clinical use for methylphenidate with tricyclic antidepressants.
Topics: Adult; Aged; Animals; Chloral Hydrate; Chromatography, Thin Layer; Depression; Desipramine; Dextroam | 1971 |
Crash treatment for melancholia. Resistant to other recently developed methods.
Topics: 5-Hydroxytryptophan; Adult; Aged; Antidepressive Agents; Blood Pressure Determination; Depression; D | 1970 |
Let the physician beware.
Topics: Depression; Fatigue; Humans; Methylphenidate; Substance-Related Disorders | 1970 |
Clinical and metabolic studies with imipramine in man.
Topics: Anxiety; Depression; Dextroamphetamine; Female; Humans; Imipramine; Male; Methylphenidate; Psychiatr | 1971 |
Methylphenidate (Ritalin).
Topics: Anorexia Nervosa; Antidepressive Agents; Anxiety; Depression; Humans; Methylphenidate; Sleep Initiat | 1969 |
[The use of ritalin in the diagnosis of depressions].
Topics: Adolescent; Adult; Depression; Diagnosis, Differential; Humans; Methylphenidate; Middle Aged | 1965 |
Antidepressive drugs.
Topics: Adolescent; Adult; Aged; Amitriptyline; Amphetamine; Antidepressive Agents; Classification; Depressi | 1965 |